Reata Pharmaceuticals up 174% in Morning Trading on Friedreich's Ataxia Drug Omaveloxolone Approval

Tiger Newspress2023-03-01

The US FDA has approved Reata Pharmaceuticals' Friedreich's ataxia (FA) treatment omaveloxolone.

Branded as Skyclarys, the drug is approved for those 16 years and older with the inherited neuronal disorder. Liver function tests are required with use.

Reata is up 174% in morning trading.The approval is the first FDA-approved therapy for the condition, which impacts ~5K in the US.

Treating the condition now involves off-label use of SSRI antidepressants, nerve pain drug Lyrica (pregabalin) for pain, and ALS drug riluzole for balance, Sheng-Han Kuo, MD, a movement disorder specialist in neurology at Columbia University Medical Center, told Seeking Alpha.

Kuo, who has done scientific consulting for Reata (RETA), said he would prescribe Skyclarys to all of his FA patients unless they are unable to tolerate it.

Other treatments in development also hold promise for FA, according to Kuo, who is the director of the Initiative for Columbia Ataxia and Tremor.

He mentioned PTC Therapeutics (PTCT) vatiquinone (PTC743), a protein replacement drug to deliver functional frataxin ("FXN") protein, and AAV gene therapy.

Following approval, Reata (RETA) received a rare pediatric disease priority review voucher.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

Leave a comment
1